Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chiglitazar + metformin
- Development stage
- Phase 3
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chiglitazar + metformin is a fixed-dose combination (FDC) therapy developed by Chipscreen Biosciences for the treatment of type 2 diabetes mellitus (T2DM). Chiglitazar is a novel small molecule peroxisome proliferator-activated receptor (PPAR) pan-agonist that targets all three PPAR isoforms (PPARα, PPARγ, and PPARδ), thereby regulating glucose and lipid metabolism and improving insulin sensitivity. Metformin is a biguanide that primarily works by inhibiting hepatic glucose production and increasing peripheral glucose uptake. This combination is formulated as an extended-release tablet and is intended for patients who have inadequate blood glucose control after treatment with metformin alone. Clinical trials have demonstrated that the combination provides continuous glucose reduction, blood lipid regulation, and potential cardiovascular risk reduction compared to metformin monotherapy.
- Brand names
- Shuangluoping
- Other names
- chiglitazar/metformin extended-release tabletschiglitazar/metformin fixed-dose combinationchiglitazar/metformin FDC
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)PPARD (Peroxisome proliferator–activated receptor delta)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on chiglitazar + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chiglitazar + metformin.